Phase III Data ENLIVEN Pexidartinib’s Prospects But Liver Tox An Issue?

Phase III results for Daiichi Sankyo’s pexidartinib presented at ASCO provide new hope in a rare tumor type with no approved therapies, but hepatic toxicity also emerged as a safety issue in the study.

Digital illustration of Cancer cell in colour background
PEXIDARTINIB A NEW HOPE IN TGCT? • Source: Shutterstock

Daiichi Sankyo Co. Ltd. presented details of promising Phase III results for its developmental cancer drug pexidartinib at the recent American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, that it says will be used to support a planned US NDA in a rare tumor type with no currently approved therapies.

One shadow lingering over the promising data however was hepatic toxicity, although the company does not appear too concerned and...

More from Anticancer

More from Therapy Areas

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.